Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed

Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics , a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been dosed at HonorHealth Research Institute in a phase 1/2 clinical trial (NCT07463599) evaluating tegavivint, a first-in-class, small molecule inhibitor of the Wnt/β-catenin pathway, for the treatment of metastatic colorectal cancer (mCRC). This milestone expands Iterion’s clinical development into mCRC, a disease with significant unmet need and limited progress in developing targeted therapies.

The release as fetched from its publisher. iteriontherapeutics.com ↗